Literature DB >> 9891044

Two polymorphic variants of wild-type p53 differ biochemically and biologically.

M Thomas1, A Kalita, S Labrecque, D Pim, L Banks, G Matlashewski.   

Abstract

The wild-type p53 protein exhibits a common polymorphism at amino acid 72, resulting in either a proline residue (p53Pro) or an arginine residue (p53Arg) at this position. Despite the difference that this change makes in the primary structure of the protein resulting in a difference in migration during sodium dodecyl sulfate-polyacrylamide gel electrophoresis, no differences in the biochemical or biological characteristics of these wild-type p53 variants have been reported. We have recently shown that p53Arg is significantly more susceptible than p53Pro to the degradation induced by human papillomavirus (HPV) E6 protein. Moreover, this may result in an increased susceptibility to HPV-induced tumors in homozygous p53Arg individuals. In further investigating the characteristics of these p53 variants, we now show that both forms are morphologically wild type and do not differ in their ability to bind to DNA in a sequence-specific manner. However, there are a number of differences between the p53 variants in their abilities to bind components of the transcriptional machinery, to activate transcription, to induce apoptosis, and to repress the transformation of primary cells. These observations may have implications for the development of cancers which harbor wild-type p53 sequences and possibly for the ability of such tumors to respond to therapy, depending on their p53 genotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9891044      PMCID: PMC116039          DOI: 10.1128/MCB.19.2.1092

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  32 in total

1.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

Authors:  L Banks; G Matlashewski; L Crawford
Journal:  Eur J Biochem       Date:  1986-09-15

3.  Oncogenic forms of p53 inhibit p53-regulated gene expression.

Authors:  S E Kern; J A Pietenpol; S Thiagalingam; A Seymour; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

4.  Primary structure polymorphism at amino acid residue 72 of human p53.

Authors:  G J Matlashewski; S Tuck; D Pim; P Lamb; J Schneider; L V Crawford
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

5.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

6.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.

Authors:  S Srivastava; Z Q Zou; K Pirollo; W Blattner; E H Chang
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

7.  Inhibition of viral and cellular promoters by human wild-type p53.

Authors:  M A Subler; D W Martin; S Deb
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 8.  Human papillomaviruses in the pathogenesis of anogenital cancer.

Authors:  H zur Hausen
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

9.  Molecular analysis of different allelic variants of wild-type human p53.

Authors:  F Moreau; G Matlashewski
Journal:  Biochem Cell Biol       Date:  1992 Oct-Nov       Impact factor: 3.626

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  204 in total

1.  P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia.

Authors:  M Bonafè; F Olivieri; D Mari; G Baggio; R Mattace; M Berardelli; P Sansoni; G De Benedictis; M De Luca; F Marchegiani; L Cavallone; M Cardelli; S Giovagnetti; L Ferrucci; L Amadio; R Lisa; M G Tucci; L Troiano; G Pini; P Gueresi; M Morellini; S Sorbi; G Passeri; C Barbi; S Valensin; D Monti; L Deiana; G M Pes; C Carru; C Franceschi
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites.

Authors:  Ulrike Haugwitz; Mark Wasner; Marcus Wiedmann; Katja Spiesbach; Karen Rother; Joachim Mössner; Kurt Engeland
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

Review 3.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

4.  Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis--a pilot study.

Authors:  Devapregasan Moodley; Girish M Mody; Anil A Chuturgoon
Journal:  Clin Rheumatol       Date:  2010-06-10       Impact factor: 2.980

5.  Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.

Authors:  Su-Qin Shen; De-Ke Jiang; Guo-Yuan Liu; Fang Chen; Long Yu
Journal:  Mol Biol Rep       Date:  2011-09-28       Impact factor: 2.316

6.  TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.

Authors:  De-Ke Jiang; Lei Yao; Wei-Hua Ren; Wen-Zhang Wang; Bo Peng; Long Yu
Journal:  Med Oncol       Date:  2010-06-15       Impact factor: 3.064

7.  RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection.

Authors:  Yee Soo Chae; Jong Gwang Kim; Sang Kyun Sohn; Su Jeong Lee; Byung Woog Kang; Joon Ho Moon; Jae Yong Park; Seong Woo Jeon; Han-Ik Bae; Gyu Seog Choi; Soo-Han Jun
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-22       Impact factor: 4.553

8.  Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.

Authors:  Maral Jamshidi; Marjanka K Schmidt; Thilo Dörk; Montserrat Garcia-Closas; Tuomas Heikkinen; Sten Cornelissen; Alexandra J van den Broek; Peter Schürmann; Andreas Meyer; Tjoung-Won Park-Simon; Jonine Figueroa; Mark Sherman; Jolanta Lissowska; Garrett Teoh Hor Keong; Astrid Irwanto; Marko Laakso; Sampsa Hautaniemi; Kristiina Aittomäki; Carl Blomqvist; Jianjun Liu; Heli Nevanlinna
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

9.  TP53 Polymorphism Contributes to the Susceptibility to Bipolar Disorder but Not to Schizophrenia in the Chinese Han Population.

Authors:  Jialei Yang; Xulong Wu; Jiao Huang; Zhaoxia Chen; Guifeng Huang; Xiaojing Guo; Lulu Zhu; Li Su
Journal:  J Mol Neurosci       Date:  2019-05-05       Impact factor: 3.444

10.  A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer.

Authors:  Sun Young Yi; Woon Jung Lee
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.